Coherus Oncology Publishes Promising Data on CCR8-Targeting Antibody Tagmokitug for Solid Tumors
核心洞察
Coherus Oncology (搜索) published preclinical and clinical data in Molecular Cancer Therapeutics showing tagmokitug (搜索) demonstrates picomolar binding affinity for CCR8 (搜索) with no off-target binding and selective elimination of regulatory T cells.
The investigational monoclonal antibody showed proof-of-mechanism in first-in-human studies, selectively reducing CCR8 (搜索)+ regulatory T cells without affecting other T cell subsets in cancer patients.
Data revealed CCR8 (搜索) is highly abundant and preferentially overexpressed in regulatory T cells across most solid tumors (搜索), supporting tagmokitug (搜索)'s broad therapeutic potential.
Coherus Oncology (搜索) announced the publication of compelling preclinical and clinical biomarker research in Molecular Cancer Therapeutics, revealing the robust pharmacological profile of its investigational anti-CCR8 (搜索) monoclonal antibody, now formally named tagmokitug (搜索). The research demonstrates the antibody's picomolar binding affinity for CCR8, complete selectivity with no off-target binding, and significant effector-mediated killing of CCR8+ cells, supporting its potential as an anticancer treatment.
The publication, appearing in the December 2025 issue of Molecular Cancer Therapeutics, provides crucial scientific evidence supporting the ongoing advancement of tagmokitug (搜索) in clinical studies evaluating its antitumor activity across multiple solid tumor settings in combination with toripalimab.
Strong Preclinical Foundation
The research revealed that CCR8 (搜索) is highly abundant and preferentially overexpressed in regulatory T cells (Tregs) within solid tumors (搜索), with most solid tumors demonstrating high levels of CCR8 expression. In mouse tumor models, anti-CCR8 antibody treatment showed anti-tumor and tumor immune remodeling activity, with enhanced efficacy when combined with anti-PD-1 (搜索) antibody treatment.
Tagmokitug (搜索) demonstrated robust characteristics including picomolar binding affinity, exquisite selectivity for CCR8 (搜索) with no off-target binding, and potent target cell killing through a bind-and-kill mechanism that induced tumor regression in mice.
Clinical Proof-of-Mechanism Established
In the first-in-human clinical study, translational data established proof-of-mechanism, showing that tagmokitug (搜索) administration leads to selective reductions in CCR8 (搜索)+ regulatory T cells without affecting other T cell subsets in cancer patients. This selective targeting profile distinguishes tagmokitug from broader immunosuppressive approaches.
"This publication presents the robust pharmacology of tagmokitug (搜索) in preclinical and clinical studies, and with a selectivity profile and potent binding and killing of CCR8 (搜索)+ T regulatory cells and not other immune cells," said Theresa LaVallee, PhD, Chief Scientific and Development Officer at Coherus. "These data provide evidence that tagmokitug has the potential for a differentiated profile."
Broad Therapeutic Potential
The data demonstrate high abundance of CCR8 (搜索) target expression across a broad range of solid tumors (搜索), suggesting promising therapeutic applications for the tagmokitug (搜索) program. LaVallee noted that the findings "show a high abundance of CCR8 target expression in a broad range of solid tumors suggesting the promise of the tagmokitug program."
Current Clinical Development
Tagmokitug (搜索) is currently being evaluated in Phase 1b/2a clinical trials in patients with advanced solid tumors (搜索), including head and neck cancer (搜索), colorectal cancer (搜索), gastric cancer (搜索), and esophageal cancer (搜索). The trials are testing tagmokitug in combination with the PD-1 (搜索) inhibitor toripalimab and chemotherapy as part of Coherus Oncology (搜索)'s next-generation immunotherapy pipeline.
The investigational monoclonal antibody selectively targets CCR8 (搜索), a receptor highly enriched on regulatory T cells within the tumor microenvironment. This targeted approach aims to enhance antitumor immune responses by depleting immunosuppressive regulatory T cells while preserving other beneficial immune cell populations.
Coherus Oncology (搜索)'s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing innate and adaptive immune responses to enable robust antitumor responses and improve outcomes for cancer patients. The company's strategy involves growing sales of its approved PD-1 (搜索) inhibitor LOQTORZI while advancing new indications in combination with pipeline candidates to drive synergies from proprietary combinations.